Latham BioPharm Group
Latham BioPharm Group provides specialized consulting services spanning the full spectrum of life sciences, supporting product development for vaccines, therapeutics, cell and gene therapies, medical devices, and diagnostics. The group offers expertise in non-dilutive funding, clinical and nonclinical development, strategic consulting, and program management, focusing on advancing products from discovery through commercialization. Their consultants deliver integrated guidance in regulatory strategy, quality assurance, manufacturing, and business development.
Industries
N/A
Services
Support throughout the clinical development lifecycle, including regulatory interactions, study documentation, CRO selection and management, SOP development, and clinical project oversight.
Advisory services for nonclinical product development and regulatory strategy, including vendor selection, study monitoring, toxicology, DMPK consulting, and specialized expertise in infectious disease and cell therapies.
Support for strategic planning, market analysis, portfolio review, financial modeling, opportunity analysis, and due diligence.
Expert guidance to match programs with relevant non-dilutive funding opportunities and navigate application and award processes.
Support throughout the clinical development lifecycle, including regulatory interactions, study documentation, CRO selection and management, SOP development, and clinical project oversight.
Advisory services for nonclinical product development and regulatory strategy, including vendor selection, study monitoring, toxicology, DMPK consulting, and specialized expertise in infectious disease and cell therapies.
Support for strategic planning, market analysis, portfolio review, financial modeling, opportunity analysis, and due diligence.
Expert guidance to match programs with relevant non-dilutive funding opportunities and navigate application and award processes.
Expertise Areas
- Cell and gene therapy
- Vaccine development
- Therapeutic products
- Non-dilutive funding
Key Technologies
- Animal modeling
- In silico drug design
- Regulatory compliance systems
Key People
Consultant, Clinical Development/Operations
Consultant, Clinical Development/Operations
News & Updates
Explores methods to optimize cost of goods for Molnupiravir production via alternative chemical synthesis methodologies.
Reports on persistent challenges that pharmaceutical companies face regarding FDA 483s, highlighting compliance issues and industry trends.
Whitepaper discussing the practical and scalability challenges for manufacturing autologous CAR-T cell therapies at commercial scale.
Presentation of modeling analysis to support low-cost manufacturing approaches for Molnupiravir, a critical COVID-19 therapeutic.
Overview of ongoing challenges in maintaining Good Manufacturing Practice compliance within the pharmaceutical and medical device industry.
Explores methods to optimize cost of goods for Molnupiravir production via alternative chemical synthesis methodologies.
Reports on persistent challenges that pharmaceutical companies face regarding FDA 483s, highlighting compliance issues and industry trends.
Whitepaper discussing the practical and scalability challenges for manufacturing autologous CAR-T cell therapies at commercial scale.
Presentation of modeling analysis to support low-cost manufacturing approaches for Molnupiravir, a critical COVID-19 therapeutic.
Overview of ongoing challenges in maintaining Good Manufacturing Practice compliance within the pharmaceutical and medical device industry.